Top Stories
The company's plan to bring provider-led GLP-1 prescribing and digital chronic care together is the first commercial offering to emerge from its partnership with Beluga Health.
Expanded partnership focuses on generating large-scale cellular datasets to train foundation models and uncover novel therapeutic targets.
Hims said the case ignores evidence it provided during a nearly three-year investigation and vowed to fight what it called "baseless claims."
Merck will contribute operational data to Evinova’s trial benchmarks, join its product steering committee and receive priority access to new tools under the multi-year agreement.
The startup's V-Link platform recently nabbed an FDA breakthrough device designation for reducing cerebral vasospasm in adults with aneurysmal subarachnoid haemorrhage.
Conference News
Company will present two scientific posters examining the operational and readiness applications of its tAN® platform, marking a key step in Spark's expansion into the military-ready and first respond...
Second Quarter Revenue Growth of 52% to $132 MillionRaises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 MillionBRISBANE, Calif.--(BUSINE...
Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and ScreeningRaises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38%PALO ALTO, Cali...
Delivered Q2 2026 revenue of $103.5 millionQ2 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 32% over Q2 2025Raising full-year 2026 revenue guidan...
Revenue of $85.4 million, growing 20.1% sequentiallyGAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-GAAP gross margin of 31.3%GAAP los...
